Clinical Updates – Page 33

Percutaneous versus Surgical Approaches in Aortic Stenosis with Complex Coronary Disease: TCW Trial Insights

By MedXY 08/02/2025

The TCW trial demonstrates that FFR-guided PCI plus TAVI is non-inferior and even superior to SAVR plus CABG in elderly patients with severe aortic stenosis and complex coronary artery disease.

Clinical Updates Hematology-Oncology news Specialties

Haematopoietic Gene Therapy Without Conditioning for Fanconi Anaemia-A: Results and Clinical Implications from the FANCOLEN-1 Trials

By MedXY 08/02/2025

Gene therapy using autologous, gene-corrected stem cells without conditioning offers sustained engraftment and reverses bone marrow failure in Fanconi anaemia-A, with a favorable safety profile.

Clinical Updates news Public Health Specialties

Efficacy of the OurFutures Vaping eHealth Intervention in Preventing Adolescent E-Cigarette Use: Insights from a Landmark Australian Cluster RCT

By MedXY 08/02/2025

A large Australian cluster RCT demonstrates that a school-based eHealth intervention, OurFutures Vaping, significantly reduces adolescent e-cigarette use by 65% compared to usual health education over 12 months.

Clinical Updates Medical News Rheumatology Specialties

Fenebrutinib in Relapsing Multiple Sclerosis: New Evidence from the FENopta Phase 2 Trial

By MedXY 08/02/2025

Fenebrutinib, a selective BTK inhibitor, demonstrated significant reduction in new brain lesions and low relapse rates in relapsing multiple sclerosis, with a favorable safety profile in the FENopta phase 2 trial.

Clinical Updates Medical News Neurology Nursing & care Specialties

Safety and Effectiveness of the Walk ‘n Watch Exercise Protocol in Inpatient Stroke Rehabilitation: Insights from a Canadian Phase 3 Stepped-Wedge Trial

By MedXY 08/02/2025

A Canadian multisite trial demonstrated that the Walk 'n Watch structured exercise protocol significantly improves walking endurance in subacute stroke patients during inpatient rehabilitation without increasing serious adverse events.

$Belantamab Mafodotin Plus Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Survival Outcomes from the DREAMM-7 Trial and Real-World Insights$

Clinical Updates Hematology-Oncology news Specialties

Belantamab Mafodotin Plus Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Survival Outcomes from the DREAMM-7 Trial and Real-World Insights

By MedXY 08/02/2025

The DREAMM-7 trial demonstrates that belantamab mafodotin with bortezomib and dexamethasone significantly improves survival in relapsed/refractory multiple myeloma, suggesting a new standard of care.

Clinical Updates Hematology-Oncology news Specialties

Fertility Outcomes in Advanced-Stage Classic Hodgkin Lymphoma: BrECADD Versus eBEACOPP in the HD21 Trial

By MedXY 08/02/2025

The HD21 trial shows BrECADD offers superior gonadal function recovery and higher parenthood rates, especially in men, compared with eBEACOPP for advanced-stage classic Hodgkin lymphoma, supporting BrECADD as the preferred first-line therapy for fertility preservation.

Clinical Updates Neurology news Specialties

Neuropsychiatric Symptoms and Their Impact on Daily Functioning in Cognitively Unimpaired Older Adults

By MedXY 08/02/2025

Neuropsychiatric symptoms such as decreased motivation and emotional dysregulation significantly impair daily functioning in older adults without cognitive impairment, highlighting the need for early identification and intervention.

Clinical Updates Neurology news Specialties

Elevated Risk of Alzheimer’s Disease and Related Dementias in Transfeminine Adults: Insights from a Large Cohort Study

By MedXY 08/02/2025

Recent data reveal that transfeminine adults experience significantly higher prevalence of Alzheimer's disease and related dementias compared to matched cisgender peers, independent of gender-affirming hormone therapy, highlighting urgent needs for targeted research and care strategies.

Clinical Updates news Ophthalmology Specialties

Alcon’s Tryptyr: A New Neuromodulatory Approach for Rapid Dry Eye Relief

By MedXY 08/02/2025

Alcon introduces Tryptyr, the first TRPM8 agonist eye drop, promising rapid tear production for dry eye disease. FDA-approved in May 2024 following robust phase 3 trials.

Clinical Updates news Ophthalmology Specialties

FDA Approves Once-Daily Vizz (Aceclidine Ophthalmic Solution 1.44%) for Presbyopia: Clinical Implications and Evidence Review

By MedXY 08/02/2025

The FDA has approved Vizz, a once-daily aceclidine ophthalmic solution, for presbyopia in adults based on robust phase 3 data. The eye drop offers up to 10 hours of improved near vision with a favorable safety profile.

Clinical Updates Diabetes & Endocrinology news Specialties

Oveporexton: A Promising Orexin Receptor 2 Agonist for Narcolepsy Type 1 – Results from a Phase 2 Randomized Trial

By MedXY 08/02/2025

Oveporexton, an oral orexin receptor 2–selective agonist, demonstrated significant improvements in wakefulness and cataplexy in narcolepsy type 1 patients over 8 weeks, with manageable adverse events.

Clinical Updates HIV/AIDS news Specialties

Advances in Second-Line Antiretroviral Therapy for Children with HIV in Africa: Insights from the CHAPAS-4 Trial

By MedXY 08/02/2025

TAF–emtricitabine and dolutegravir-based regimens outperform standard options as second-line ART for African children with HIV, offering improved viral suppression and safety.

Allergy & Immunology Clinical Updates news Rheumatology Specialties

Comparative Efficacy and Safety of Tolebrutinib in Multiple Sclerosis: Insights from Recent Phase 3 Trials

By MedXY 08/02/2025

Tolebrutinib reduced disability progression in nonrelapsing secondary progressive MS but did not surpass teriflunomide in reducing relapse rates in relapsing MS. Safety signals include elevated liver enzymes and minor bleeding risks.

Clinical Updates news Respiratory Specialties

Sotatercept in High-Risk Pulmonary Arterial Hypertension: A Landmark Advance in Patient Outcomes

By MedXY 08/02/2025

Sotatercept significantly reduces the risk of death, lung transplantation, or hospitalization in high-risk pulmonary arterial hypertension patients, marking a major advance in the management of this life-threatening disease.

Clinical Updates news Rheumatology Specialties

Upadacitinib and Janus Kinase Inhibitors in Giant-Cell Arteritis: Clinical Trial and Real-World Evidence

By MedXY 08/02/2025

Upadacitinib at 15 mg with a 26-week glucocorticoid taper shows superior efficacy and comparable safety to placebo in giant-cell arteritis. Real-world data suggest JAK inhibitors, including upadacitinib, may benefit relapsing cases unresponsive to conventional therapies.

Clinical Updates news Respiratory Specialties

Navigational Bronchoscopy Versus Transthoracic Needle Biopsy for Peripheral Lung Nodules: New Evidence from the VERITAS Trial

By MedXY 08/02/2025

Navigational bronchoscopy offers noninferior diagnostic accuracy to transthoracic needle biopsy for peripheral pulmonary nodules, with notably fewer pneumothorax complications.

Clinical Updates news Oncology Specialties

Regional Nodal Irradiation After Neoadjuvant Chemotherapy: Is Omission Safe for Breast Cancer Patients with ypN0 Status?

By MedXY 08/01/2025

A landmark trial shows that omitting regional nodal irradiation after neoadjuvant chemotherapy in breast cancer patients with ypN0 status does not compromise recurrence or survival outcomes.

Clinical Updates news OB/GYN & Women's Health Pediatrics Specialties

Trimethoprim–Sulfamethoxazole in Pregnancy: No Impact on Birth Weight in a Zimbabwean RCT

By MedXY 08/01/2025

A large randomized trial in Zimbabwe found that trimethoprim–sulfamethoxazole prophylaxis during pregnancy did not significantly increase birth weight or reduce adverse outcomes.

Clinical Updates Hematology-Oncology news Specialties

Durable Efficacy and Long-term Safety of AAV Gene Therapy in Severe Hemophilia B: 13-Year Follow-up Results

By MedXY 08/01/2025

A single AAV gene therapy infusion for severe hemophilia B led to sustained factor IX expression, substantial reduction in bleeding and factor use, and no late safety concerns over 13 years.